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Background
P. vivax is the most geographically widespread human
malaria and is considered to be the most prevalent form in
some regions of Latin America, Central and South-East
Asia, accounting for up to 390 million clinical infections
every year and an estimated 2.6 billion people being at risk
of infection with P. vivax [1,2]. An effective vaccine against
this protozoan would have a major global impact on the
disease burden [3]. Modified Vaccinia Ankara (MVA) and
the chimpanzee adenovirus ChAd63 are two clinically
relevant viral vectors that have been shown to induce
strong and protective antibody and T-cell responses
against P. falciparum TRAP, both in pre-clinical studies
and clinical trials [4-7].
Materials and methods
We developed recombinant ChAd63 and MVA vectors
expressing P. vivax TRAP (PvTRAP), which were used to
assess T-cell and antibody responses upon sequential
immunisation (prime-boost) of mice. Vaccine efficacy was
assessed through challenge with a newly developed trans-
genic P. berghei expressing PvTRAP.
Results
High antibody titres and frequencies of PvTRAP-specific
T cells were induced in all tested inbred and outbred
mouse strains. The newly developed parasite showed
similar fitness to wild type P. berghei and was successfully
used to infect and assess protection in vaccinated mice.
The Ad-MVA prime-boost regimen induced good pro-
tective levels regardless of the mouse strain.
Conclusions
The strong immunogenicity and protective efficacy elicited
by the recombinant ChAd63 and MVA viruses expressing
PvTRAP indicate that this vaccine approach has a good
potential to be tested in clinical trials in the near future.
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